Las Vegas Sands [LVS] - Last Close: $59.36
An upbeat earnings report is giving Las Vegas Sands a boost today.
The casino operator released its Q1 results late Wednesday, and the market likes what it sees.
Las Vegas Sands reported Q1 adjusted diluted earnings pf $0.28 per share, swinging to a profit after reporting a $(0.40) per share loss a year ago.
Quarterly revenues came in at $2.12 billion, up from $943 million in the year-earlier quarter.
Analysts' expected EPS of $0.20 on revenues of $1.83 billion.
LVS is leading the S&P 500 with a 5.5% gain on the news.
My Take: LVS has been facing stiff resistance at $60 per share since the beginning of February, but this rally could give it the boost it needs to breakthrough and set a new high.
United Insurance Holdings [UIHC] - Last Close: $1.65
United Insurance Holdings is moving higher after an announcement.
The property & casualty insurance company announced a new memorandum of understanding with Florida's Dept. of Financial Services (DFS).
According to the 10-K Filing, the memo of understanding pertained to a Reinsurance Allocation Agreement between DFS and a UIHC subsidiary.
The allocation agreement becomes effective June 1st, and DFS will adopt, ratify, and affirm the deal.
The agreement settled an ongoing dispute regarding repayment from losses associated with Hurricane Ian.
UIHC is one of this morning's top performers with a 41.8% gain.
My Take: UIHC experienced a steep sell off earlier this week, but it could be on course for a rebound after today's news. It could be worth watching, but expect some volatility.
Sonnet Biotherapeutics [SONN] - Last Close: $0.3038
Upbeat drug data is boosting shares of Sonnet Bio.
The clinical-stage oncology biotech highlighted encouraging data from ongoing Phase 1 trials of SON-1010 in cancer patients.
Sonnet said it's now enrolling the final dose cohort in the trial, and, so far, the drug has been safe and tolerable at all doses.
The company also reported that some patients experienced tumor shrinkage as a result of receiving the experimental therapeutic.
Several analysts released bullish notes on SONN shortly after the news dropped, including EF Hutton & Chardan Capital.
SONN is this morning's most active stock, and it's up 36.3%.
My Take: This is a very small-float biotech with an ugly chart. I would have to see more evidence of a swing higher before I thought about chasing this one.
MDxHealth SA [MDXH] - Last Close: $3.34
MDxHealth is rallying after a recent announcement.
After Wednesday's close, the Belgium-based diagnostics firm announced its Select mdx for Prostate Cancer test has met coverage conditions.
The diagnostic passed a rigorous technical assessment process with the Molecular Diagnostic Services Program developed by Palmetto GBA.
Select mdx can now be reimbursed throughout the U.S. for Medicare patients who qualify under the foundational Local Coverage Determination for increased risk of prostate cancer.
The proprietary urine-based mRNA test offers a non-invasive method to assess a patientâs risk for clinically significant prostate cancer.
MDXH is up 26.2% on news of the diagnostic test's approval.
My Take: There are some promising signs beginning to develop in MDXH's chart, and share prices were more than 100% higher just a couple of months ago. This stock could have some notable upside ahead of it if it can continue to execute.
